Cell cycle aberrations in the pathogenesis of squamous cell carcinoma of the uterine cervix

被引:38
作者
Clarke, B [1 ]
Chetty, R [1 ]
机构
[1] Nelson R Mandela Med Sch, Dept Anat Pathol, Sch Pathol & Lab Med, Durban, South Africa
关键词
D O I
10.1006/gyno.2001.6306
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer cells are characterized by limitless proliferative autonomy and immunity to inhibitory and apoptotic signals, thus ensuring growth and metastasis [1]. Epidemiological studies have long implicated human papillomavirus (HPV) as a pathogenic agent in cervical cancer. Progress in cancer research now provides an understanding of how these characteristics are achieved by the interaction of BPV proteins with the cell cycle machinery. Expression of oncoproteins E7 and E6 induces immortalization of cells through their inhibitory effects on tumor suppressor proteins pRb and p53, respectively. Undermining of pRb's growth-inhibitory role with release of E2F transcription factors renders the cells independent of mitogenic stimuli. The abundance of growth transcription factors grants limitless proliferative potential by allowing expression of products such as cyclins A, E, and B, dihydrofolate reductase, and DNA polymerase which fuel the various stages of the cell cycle. There is subsequent disruption of both the G(1)-S and G(2)-M cell cycle checkpoints. Overexpression of cyclin E results in chromosomal instability and possible unmasking of genetic mutations, allowing disease progression. Cyclin A grants anchorage-independent growth, facilitating tissue invasion and tumor spread. Apoptotic and growth-inhibitory mechanisms are also evaded. p53 is degraded by E6 and its own downstream protein mdm2. Its other downstream protein, p21 is rendered ineffective against cyclin-cyclin-dependent kinase units by E7, as is p27. The understanding of the molecular pathology of disease will provide us with the ability to prognosticate and treat patients more effectively. (C) 2001 Academic Press.
引用
收藏
页码:238 / 246
页数:9
相关论文
共 110 条
[1]   P53 CONTROLS BOTH THE G(2)/M AND THE G(1) CELL-CYCLE CHECKPOINTS AND MEDIATES REVERSIBLE GROWTH ARREST IN HUMAN FIBROBLASTS [J].
AGARWAL, ML ;
AGARWAL, A ;
TAYLOR, WR ;
STARK, GR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (18) :8493-8497
[2]   CYCLIN D1 PROTEIN EXPRESSION AND FUNCTION IN HUMAN BREAST-CANCER [J].
BARTKOVA, J ;
LUKAS, J ;
MULLER, H ;
LUTZHOFT, D ;
STRAUSS, M ;
BARTEK, J .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (03) :353-361
[3]   Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis [J].
Belinsky, SA ;
Nikula, KJ ;
Palmisano, WA ;
Michels, R ;
Saccomanno, G ;
Gabrielson, E ;
Baylin, SB ;
Herman, JG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :11891-11896
[4]  
Boyer SN, 1996, CANCER RES, V56, P4620
[5]   P53 MUTATIONS IN CERVICAL CARCINOGENESIS LOW-FREQUENCY AND LACK OF CORRELATION WITH HUMAN PAPILLOMAVIRUS STATUS [J].
BUSBYEARLE, RMC ;
STEEL, CM ;
WILLIAMS, ARW ;
COHEN, B ;
BIRD, CC .
BRITISH JOURNAL OF CANCER, 1994, 69 (04) :732-737
[6]   FREQUENT SOMATIC MUTATIONS AND HOMOZYGOUS DELETIONS OF THE P16 (MTS1) GENE IN PANCREATIC ADENOCARCINOMA [J].
CALDAS, C ;
HAHN, SA ;
DACOSTA, LT ;
REDSTON, MS ;
SCHUTTE, M ;
SEYMOUR, AB ;
WEINSTEIN, CL ;
HRUBAN, RH ;
YEO, CJ ;
KERN, SE .
NATURE GENETICS, 1994, 8 (01) :27-32
[7]   Dual cyclin-binding domains are required for p107 to function as a kinase inhibitor [J].
Castaño, E ;
Kleyner, Y ;
Dynlacht, BD .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (09) :5380-5391
[8]   Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer [J].
Catzavelos, C ;
Bhatacharya, N ;
Ung, YC ;
Wilson, JA ;
Roncari, L ;
Sandhu, C ;
Shaw, P ;
Yeger, H ;
MoravaProtzner, I ;
Kapusta, L ;
Franssen, E ;
Pritchard, KI ;
Slingerland, JM .
NATURE MEDICINE, 1997, 3 (02) :227-230
[9]  
CHEN TM, 1993, ONCOGENE, V8, P1511
[10]   Cyclin D1 and retinoblastoma protein expression in oesophageal squamous cell carcinoma [J].
Chetty, R ;
Chetty, S .
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1997, 50 (05) :257-260